Pilzinfektionen auf der Intensivstation

nvasive Mykosen bei intensivmedizinisch betreuten Patient*innen sind komplex: häufig werden sie erst spät erkannt, die Diagnose ist schwierig und die Morbidität und Mortalität sind hoch. Die häufigsten Pilznachweise bei intensivmedizinisch behandelten Patient*innen sind Candida species, Aspergillus species und Pneumocystis jirovecii. Besonders bei kritisch kranken oder immunsupprimierten Patient*innen können invasive Mykosen rasch lebensbedrohlich verlaufen. Eine frühe, gezielte Diagnostik ist entscheidend für Therapie und Prognose.

Schlüsselwörter

Candidämie - invasive Candidiasis - Pneumocystis jirovecii - PCP - invasive Aspergillose

• Literatur

• 1 Koehler P, Cornely OA. Contemporary Strategies in the prevention and management of fungal infections. Infect Dis Clin North Am 2016; 30: 265-275
• 2 Bassetti M, Giacobbe DR, Agvald-Ohman C. et al. Invasive fungal diseases in adult patients in intensive care unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM. Intensive Care Med 2024; 50: 502-515
• 3 Hoenigl M, Seidel D, Sprute R. et al. COVID-19-associated fungal infections. Nat Microbiol 2022; 7: 1127-1140
• 4 Koehler P, Stecher M, Cornely OA. et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect 2019; 25: 1200-1212
• 5 Hinrichs C, Wiese-Posselt M, Graf B. et al. Successful control of Candida auris transmission in a German COVID-19 intensive care unit. Mycoses 2022; 65: 643-649
• 6 Koehler P, Bassetti M, Kochanek M. et al. Intensive care management of influenza-associated pulmonary aspergillosis. Clin Microbiol Infect 2019; 25: 1501-1509
• 7 Koehler P, Bassetti M, Chakrabarti A. et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021; 21: e149-e162
• 8 Koehler P, von Stillfried S, Garcia Borrega J. et al. Aspergillus tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study. Eur Respir J 2022; 59: 2103142
• 9 Salmanton-García J, Sprute R, Stemler J. et al. COVID-19-Associated pulmonary aspergillosis, March-August 2020. Emerg Infect Dis 2021; 27: 1077-1086
• 10 Hänsel L, Schumacher J, Denis B. et al. How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia?. Clin Microbiol Infect 2023; 29: 1015-1023
• 11 Chow JK, Golan Y, Ruthazer R. et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008; 36: 1993-1998
• 12 Wisplinghoff H, Bischoff T, Tallent SM. et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317
• 13 Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis 2024; 24: e428-e438
• 14 Cornely OA, Sprute R, Bassetti M. et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis 2025;
• 15 Bloos F, Held J, Kluge S. et al. (1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Med 2022; 48: 865-875
• 16 Hoenigl M, Salmanton-García J, Egger M. et al. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Lancet Infect Dis 2023; 23: 751-761
• 17 Mellinghoff SC, Hoenigl M, Koehler P. et al. EQUAL Candida Score: An ECMM score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses 2018; 61: 326-330
• 18 Blot S, Rello J, Koulenti D. Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together. Curr Opin Crit Care 2019; 25: 430-437
• 19 Donnelly JP, Chen SC, Kauffman CA. et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71: 1367-1376
• 20 Ullmann AJ, Aguado JM, Arikan-Akdagli S. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018; 24 (Suppl. 1) e1-e38
• 21 Maertens JA, RaadMarr KA. et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016; 387: 760-769
• 22 Maertens JA, Rahav G, Lee DG. et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet 2021; 397: 499-509
• 23 Marr KA, Schlamm HT, Herbrecht R. et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162: 81-89
• 24 Cornely OA, Koehler P, Arenz D. et al. EQUAL Aspergillosis Score 2018: An ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. Mycoses 2018; 61: 833-836
• 25 Sehgal IS, Muthu V, Seidel D. et al. EQUAL ABPA Score 2024: a tool to measure guideline adherence for managing allergic bronchopulmonary aspergillosis. Mycoses 2024; 67: e13810
• 26 Sprute R, Van Braeckel E, Flick H. et al. EQUAL CPA Score 2022: a tool to measure guideline adherence for chronic pulmonary aspergillosis. J Antimicrob Chemother 2022; 78: 225-231
• 27 Redhead SA, Cushion MT, Frenkel JK. et al. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol 2006; 53: 2-11
• 28 Giacobbe DR, Dettori S, Di Pilato V. et al. Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG. Crit Care 2023; 27: 323
• 29 Choukri F, Menotti J, Sarfati C. et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010; 51: 259-265
• 30 Kaplan JE, Benson C, Holmes KK. et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1-207 quiz CE1–CE4
• 31 Roblot F, Le Moal G, Kauffmann-Lacroix C. et al. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. Scand J Infect Dis 2014; 46: 210-214
• 32 Alanio A, Hauser PM, Lagrou K. et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; 71: 2386-2396
• 33 Senécal J, Smyth E, Del Corpo O. et al. Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect 2022; 28: 23-30
• 34 Takemoto S, Ebara M, Hasebe S. et al. A study on the colonization of Pneumocystis jirovecii among outpatients during cancer chemotherapy and among healthy smokers. J Infect Chemother 2017; 23: 752-756
• 35 Kamel T, Janssen-Langenstein R, Quelven Q. et al. Pneumocystis pneumonia in intensive care: clinical spectrum, prophylaxis patterns, antibiotic treatment delay impact, and role of corticosteroids. A French multicentre prospective cohort study. Intensive Care Med 2024; 50: 1228-1239
• 36 Wieruszewski PM, Barreto JN, Frazee E. et al. Early corticosteroids for pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest 2018; 154: 636-644
• 37 Maschmeyer G, Helweg-Larsen J, Pagano L. et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 2016; 71: 2405-2413
• 38 Vogel MN, Vatlach M, Weissgerber P. et al. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol 2012; 81: 1315-1320